

Talent Pool



EXECUTIVE APPOINTMENTS
AND PROMOTIONS IN THE
HEALTHCARE INDUSTRY

► PHARMA POOL

John Demaree ASTELLAS PROMOTES VP OF ONCOLOGY MARKETING IN THE AMERICAS REGION



John Demaree

Astellas has promoted John Demaree to VP, oncology marketing, Astellas Americas. In this role, Mr. Demaree is leading Astellas' oncology marketing team in promotion of in-market products, preparation for new oncology product launches and strategic planning and collaboration with the company's partner organizations in the Americas region.

He has more than 25 years of experience working in the pharmaceutical industry, with more than 20 years in oncology. Before his promotion, Mr. Demaree served as executive director, oncology marketing, where he helped execute the launch of Xtandi and promotion of Tarceva.

Michael Minarich SIGMA-TAU PHARMACEUTICALS NAMES CEO



Michael Minarich

Sigma-Tau Pharmaceuticals has appointed Michael Minarich as CEO, a role he has severed in an interim role since July 2015.

Before joining Sigma-Tau Pharmaceuticals, Mr. Minarich was providing consulting services to start-ups and early- and mid-stage companies in the biosciences and specialty pharmaceutical industries. He spent the previous 20 years as an expatriate in Asia (Seoul), Canada (Montreal) and Europe (Brussels & Prague) as the Market Company President, Czech Republic for Pharmacia Corporation and at legacy company, G.D. Searle / Monsanto, with increasing responsibilities in international general management, marketing, and business development.

► BIOTECH POOL

Christopher Lowe INSPIR THERAPEUTICS APPOINTS CEO

Inspyr Therapeutics, a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, has named Christopher Lowe president and CEO.

Mr. Lowe brings to Inspyr Therapeutics more than 15 years of executive management experience in life sciences.

Dr. Amy Peterson BEIGENE APPOINTS CHIEF MEDICAL OFFICER

BeiGene, a clinical-stage biopharmaceutical com-

pany focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, has appointed Amy Peterson, M.D., as chief medical officer, immuno-oncology.

Before joining BeiGene, Dr. Peterson was VP of clinical development at Medivation, where she was primarily responsible for the development of enzalutamide and talazoparib in breast cancer and of pidilizumab in diffuse large b-cell lymphoma.

► BIOPHARMA POOL

Dr. Robert Kim APELLIS PHARMACEUTICALS APPOINTS CHIEF MEDICAL OFFICER



Dr. Robert Kim

Apellis Pharmaceuticals, a clinical-stage complement immunotherapy company, has expanded its executive team with the addition of Dr. Robert Kim as its Chief Medical Officer. Dr. Kim will help the company optimize its drug development strategy as its clinical programs progress toward late stage clinical testing.

Dr. Kim has more than 30 years of clinical experience in ophthalmology, most recently serving at the retina startup Vision Medicines, where he was chief medical officer and head of R&D. He is also currently associate clinical professor of ophthalmology at UCSF.

Dr. Jerome Zeldis SORRENTO NAMES CHIEF MEDICAL OFFICER AND PRESIDENT OF CLINICAL DEVELOPMENT




Dr. Jerome Zeldis

Sorrento Therapeutics, an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, has named Jerome Zeldis, M.D., Ph.D., chief medical officer and president of clinical development. Dr. Zeldis joins Sorrento after a nearly 20-year career at Celgene. Most recently, Dr. Zeldis held the position of CEO of Celgene Global Health and chief medical officer of Celgene.

► BIOTECH POOL

Elizabeth Crowley CELLEX APPOINTS CHIEF PRODUCT DEVELOPMENT OFFICER

Celldex Therapeutics has promoted Elizabeth Crowley to the newly created position of senior VP, chief product development officer. Ms. Crow-



Elizabeth Crowley

ley was previously senior VP of product development of Celldex and brings almost 25 years of industry experience where she was responsible for leading the execution of multiple successful drug development programs.

► AGENCY PHARMA


Sarah Bast Erica Schneider Lisa Turzio RAZORFISH HEALTH ANNOUNCES THE PROMOTIONS OF THREE ACCOUNT LEADERS



Sarah Bast



Erica Schneider



Lisa Turzio

Razorfish Health, an integrated health marketing agency, has promoted three members of account management team. Sarah Bast has been promoted to VP, group account director. Erica Schneider has been promoted to VP, account director. And Lisa Turzio has been promoted to senior VP, group account director.

As VP, group account director, Ms. Bast is charged with providing strategic oversight and direction for one of the agency's largest clients. Her vast expertise in the development of multi-channel digital campaigns spans across online advertising, search engine marketing and electronic health records.

Ms. Schneider brings early mover perspective to the agency's digital offering, along with deep experience in developing omni-channel marketing strategies.

Ms. Turzio brings a highly collaborative spirit and transformative thinking to the creation of fully integrated, multi-channel programs for health systems and their customers. She is responsible for building a team that delivers best-in-class business intelligence across professional and consumer platforms.

Dr. Barbara LePetri THE BLOC WELCOMES NEW SENIOR VP DIRECTOR OF MEDICAL & SCIENTIFIC SERVICES

The Bloc has appointed Barbara LePetri, M.D., to lead the medical strategy team as senior VP director of medical and scientific services. Dr. LePetri is charged

with driving scientific strategy innovation at The Bloc, expanding the team of medical experts.

Eric Steckelman
GIANT WELCOMES BACK CHIEF GROWTH OFFICER



Giant Creative/Strategy, a full-service independent health-care communications agency, welcomes back industry expert Eric Steckelman as chief growth officer. In this newly created role, Mr. Steckelman oversees the company's business development, client services, and core strategic functions.

Mr. Steckelman previously was senior VP, managing director at Giant from 2012 to 2015.

Joe Tardibuono
HEALTHSTAR COMMUNICATIONS HIRES INDUSTRY VETERAN AS EXECUTIVE VP



HealthSTAR Communications, a healthcare communications company, comprised of a fully integrated network of companies including Centron Advertising, Centron PR, Centron Market Access, HealthSTAR CES, HealthSTAR Meetings and Events, HealthSTAR Virtual and HealthSTAR Medical Education, has brought on Joe Tardibuono as executive VP. Mr. Tardibuono, who has 20-plus years of healthcare experience, joins HealthSTAR from Hudson Global.

► **SERVICE POOL**

Daryl Gaugler
SPECTRA BIOPHARMA SELLING SOLUTIONS NAMES PRESIDENT

Spectra BioPharma Selling Solutions (Spectra) has named Daryl Gaugler as president of the company. Mr. Gaugler joins Spectra's existing management team of industry leaders and provides strategic direction and oversee the day-to-day execution of the contract sales organization formed early this year.

Dr. Peter Khoury
NANOTHERAPEUTICS NAMES CHIEF COMMERCIAL OFFICER

Nanotherapeutics, a contract development and manufacturing organization (CDMO), has named Peter Khoury,

Ph.D., as senior VP and chief commercial officer. Before joining Nanotherapeutics, from 2014 until the present, Dr. Khoury was with the Bill & Melinda Gates Foundation, serving as senior program officer, life science partnerships, office of the president for global health. **PV**

6th Annual PODD
PARTNERSHIPS IN DRUG DELIVERY

OCTOBER 27 - 28, 2016

FAIRMONT COPLEY PLAZA, BOSTON, MA

FEATURING THE WIDEST RANGE OF DRUG DELIVERY TECHNOLOGIES

2016 KEYNOTES



Robert Langer, PhD
David H. Koch Institute Professor
MIT



George Church, PhD
Robert Winthrop Professor of Genetics
Harvard Medical School



Mjr Imran, MS
Chairman & CEO
InCube Labs



Jorg Thommes, PhD
SVP, Technical Development
Biogen

2016 CHAIRS



Conference Chair
Barbara Lueckel, PhD
Roche



Injectable Formulation Technologies Chair
Ann Daugherty, PhD
Genentech



Non-Injectable Formulation Technologies Chair
Mark Wilson, PhD
GSK and SR One



Drug Delivery Device Technologies Chair
Ullrich Bruggemann
Sanofi

500+ Meetings

90+ Speakers

300+ Attendees

60+ Drug Delivery Technologies

15% Discount for PharmaVoice readers with code PVCE15

Organized by



www.theconferenceforum.org

Media Partner



(c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact mwals@pharmavoices.com